Japan’s Takeda to buy Swiss drugmaker
Takeda, Japan’s largest pharmaceutical company, has announced plans to buy Swiss rival Nycomed for $13.6 billion (SFr12 billion).
Nycomed, which has its headquarters in Zurich, is a privately-owned company that produces a variety of prescription as well as over the counter products.
“Nycomed gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda’s European sales,” said Takeda CEO Yasuchika Hasegawa in a statement on Thursday.
Takeda is known for Actos, its diabetes drug. Nycomed’s lung drug roflumilast – known as Daxas in Europe and Daliresp in the United States – is used to treat chronic obstructive pulmonary disease.
The deal would not include Nycomed’s US dermatology unit.
More
Meet the foreigners who make up a quarter of the Swiss population
More
Russian investigation confirms Putin’s son was born in Switzerland
More
The mystery of Switzerland’s surging imports of Uzbek and Kazakh gold
More
Switzerland’s struggle: balancing architecture, densification and heritage
More
Thawing permafrost decoded by breakthrough Swiss research
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.